C. difficile Infection
Harnessing the power of the gut microbiota with precision therapeutic innovations that help transform patients' lives
CDI (C. difficile infection)
C. difficile infection (CDI or C. diff.) is an insidious disease which can be debilitating, characterized by watery diarrhea and abdominal cramping and may be accompanied by nausea, fever, and dehydration. C. diff. can also result in more serious disease complications, including bowel perforation (a tear in the gastrointestinal tract), sepsis, and potentially death. It necessitates patient isolation because of its highly contagious nature, making it able to be passed from one person to another either in a hospital or long-term care facility setting, as well as in the community.
C. diff is a bacterial infection caused by the bacteria, Clostridioides difficile, that produces toxins causing inflammation of the colon. And the current standard of care is not solving the complete issue: broad-spectrum antibiotic treatment is a standard therapy for C. diff., but dysbiosis of the gut microbiota due to broad-spectrum antibiotic exposure is also a major risk factor for the disease. In addition, recurrence following an initial infection is a major issue, where persistent treatment-related dysbiosis predisposes the patient to subsequent recurrence.
Ridinilazole is an investigational therapy that is being studied for the treatment of and the reduction of recurrence of C. difficile infection. Ridinilazole is not approved by any regulatory authority, and commercialization of ridinilazole is subject to regulatory approvals.
Cases per year in the US
Annual acute care costs, with 20,000 – 30,000 deaths per year in the US
Recurrence is a primary clinical issue in CDI, as up to 25% of initial cases of CDI result in a second episode; the risk of recurrence rises to 65% after a third episode
The highest threat designation by the US CDC; C. difficile is one of only four bacteria to carry that label, requiring immediate, aggressive action
Latest Research Publications
C. difficile infection / 25 Apr 2022
Transcriptomic analysis of the Clostridioides difficile-targeting antimicrobial ridinilazole implicates disruption of energy-generation pathways as its mechanism of action
Clive S Mason et al. ECCMID 2022
C. difficile infection / 15 Oct 2021
Characterization of the DNA binding properties of ridinilazole, a phase III antibiotic for treatment of Clostridioides difficile Infection
C. Mason et al. IDWeek 2021
C. difficile infection / 12 Jul 2021
Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study
E. Duperchy et al. ECCMID 2021